From each protocol established in the operating room, to the ICU, to the daily administration of patient care on the in-patient wards, everything your acute care teams do is meant to set the stage for the best possible patient outcomes. Preventing infections by eliminating the bacteria in a patient’s own skin flora has been one of the prevailing protocols designed to achieve this goal. But once you kill all the bugs on the skin, what happens next?
The skin is the largest organ system in the human body, making up roughly 16% of our body weight. When healthy, it performs a variety of defensive functions and plays a vital role in immune health. It’s worth considering the role of topical antiseptic drugs in an acute setting—including bathing and surgical prep—and whether they interfere with the skin’s defensive capabilities and actually inhibit healing, or whether they support the skin’s defense system and stage the patient for better outcomes.
What Is a S.M.A.R.T. Approach to Staging Patients for Better Outcomes?
The state of a patient’s skin is a major factor in patient outcomes:
Harness the Power of a Patient’s Skin Defense System to Improve Patient Outcomes
Staging your patient for the best outcomes means ensuring the skin is supported before and after surgery, in the ICU, and in other acute bathing scenarios. Contact us to learn about a S.M.A.R.T. approach to patient staging with Theraworx Protect.
- Elias PM. The skin barrier as an innate immune element. Semin Immunopathol. 2007;29(1):3-14.
- Pappas A. Epidermal surface lipids. Dermatoendocrinol 2009; 1(2): 72-76. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835894/.
- Philippe HB, Yves FD. Force matters in hospital-acquired infections. Science. 2018;359(6383):1464-1465.
- Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis. 2002;8(9):881–890. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2732559/. August 15, 2019.
- United Nations Interagency Coordination Group on Antimicrobial Resistance. Report to the Secretary-General of the United Nations. No time to wait: securing the future from drug-resistant infections. Available from: https://www.who.int/antimicrobial-resistance/interagency-coordination-group/IACG_final_report_EN.pdf?ua=1. Accessed May 22, 2019.
- Schittek B, Paulmann M, Senyurek I, Steffen H. The role of antimicrobial peptides in human skin and in skin infectious diseases. Infect Disord Drug Targets. 2008 Sep;8(3):135-43.
- Duplantier AJ, van Hoek ML. The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. Front Immunol. 2013; 4: 143. Available from: https://doi.org/10.3389/fimmu.2013.00143. Accessed 14 August 2019.
- Lopez-Garcia B., Lee P.H.A., Yamasaki K., Gallo R.L. Anti-fungal activity of cathelicidins and their potential role in candida albicans skin infection. J Investig Dermatol. 2005;125:108–115. Available from: https://www.jidonline.org/article/S0022-202X(15)32351-4/fulltext Accessed August 14, 2019.
- Malik E, Dennison SR, Harris F, Phoenix DA. pH Dependent Antimicrobial Peptides and Proteins, Their Mechanisms of Action and Potential as Therapeutic Agents. Pharmaceuticals (Basel). 2016;9(4):67 Available from: https://www.mdpi.com/1424-8247/9/4/67/htm Accessed August 14, 2019.
- Nagoba B, Suryawanshi N, Wadher B, Selkar S. Acidic environment and wound healing: a review. Wounds. 2015;27:5-11. Available from: https://www.woundsresearch.com/article/acidic-environment-and-wound-healing-review. Accessed July 12, 2019.